Cargando…
Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia
BACKGROUND: This 13-week, double-blind study was conducted to confirm the efficacy and safety of paliperidone palmitate (PP), at dosing regimens approved in other countries, in Asian patients with schizophrenia. METHODS: Asian patients (aged ≥20 years) diagnosed with schizophrenia (Diagnostic and St...
Autores principales: | Takahashi, Nagahide, Takahashi, Masayoshi, Saito, Takayuki, Iizumi, Misuzu, Saito, Yuki, Shimizu, Hiroko, Matsumura, Taka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862510/ https://www.ncbi.nlm.nih.gov/pubmed/24353421 http://dx.doi.org/10.2147/NDT.S54051 |
Ejemplares similares
-
Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study
por: Savitz, Adam J, et al.
Publicado: (2017) -
PM394. The outcome of paliperidone palmitate in schizophrenia
por: Ju, Po-Chung
Publicado: (2016) -
Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan
por: Mahlich, Jörg, et al.
Publicado: (2015) -
Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
por: Einarson, Thomas R, et al.
Publicado: (2012) -
Population Pharmacokinetics of Paliperidone Palmitate (Once‐Monthly Formulation) in Japanese, Korean, and Taiwanese Patients With Schizophrenia
por: Shimizu, Hiroko, et al.
Publicado: (2019)